Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.83 and traded as low as $0.81. Spero Therapeutics shares last traded at $0.82, with a volume of 474,644 shares.
Analysts Set New Price Targets
Separately, HC Wainwright reduced their price objective on Spero Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, August 15th.
Spero Therapeutics Stock Down 6.7 %
The stock has a market capitalization of $28.81 million, a price-to-earnings ratio of -0.24 and a beta of 1.87. The business has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $2.83.
Institutional Investors Weigh In On Spero Therapeutics
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.
- Get a free copy of the StockNews.com research report on Spero Therapeutics (SPRO)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.